VHT vs XBI.
Vanguard Health Care ETF (MSCI US IMI Health Care 25/50) against SPDR S&P Biotech ETF (S&P Biotechnology Select Industry) — fees, long-horizon total returns, holdings overlap, and sector tilt, side by side.
| VHT | XBI | SPREAD | |
|---|---|---|---|
| YTD (cumulative) | — | +24.8% | — |
| 1Y CAGR | — | +73.9% | — |
| 3Y CAGR | — | +21.9% | — |
| 5Y CAGR | — | +3.97% | — |
| 10Y CAGR | — | +10.4% | — |
| Since inception CAGR | — | +11.8% | — |
Total return: dividend- and split-adjusted daily closes (distributions reinvested). Spread is VHT minus XBI. XBI since-inception measured from first available bar February 6, 2006. Since-inception spans differ — compare that row with care.
| VHT | XBI | |
|---|---|---|
| Name | Vanguard Health Care Index Fund ETF Shares | State Street SPDR S&P Biotech ETF |
| Category | Health | Health |
| Style | Passive | Passive |
| Expense ratio | 0.09% | 0.35% |
| Assets (AUM) | $20.4B | $10.7B |
| Dividend yield | 1.58% | 0.36% |
| Avg volume (3-mo) | 253K | 8.9M |
| Inception | January 26, 2004 | January 31, 2006 |
| Benchmark proxy | S&P 500 | S&P 500 |
VHT costs 0.26 pp less per year — about $26.00 per $10,000 invested.
Sum of min(weight in each fund) across shared tickers — the standard fund-overlap measure. Computed on the top 25 holdings each fund reports, so it is a lower bound; the coverage figures show how much of each fund those top holdings represent.